# Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

> **NCT06751602** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **The Methodist Hospital Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Rejection Chronic Renal

## Interventions

- **DRUG:** Belumosudil 200 mg QD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06751602
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-11
- **Primary completion:** 2027-12
- **Final completion:** 2028-03-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751602, "Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06751602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*